Deals
Oral Weight-Loss Drug Developer Kallyope Exploring IPO
This article is for subscribers only.
Kallyope Inc., a US biotech that’s developing oral weight loss drugs, is exploring an initial public offering, according to people familiar with the matter, as the company seeks to capitalize on the investor frenzy around treatments for obesity.
The New York-based company is working with lead underwriter JPMorgan Chase & Co. on a potential listing for this year, said the people, who asked not to be identified because the matter is confidential.